Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.

Gong J, Yang R, Zhou M, Chang LJ

Open source

DOI
10.1186/s10020-023-00680-z
Published
2023 Jun 12
Container
Molecular medicine (Cambridge, Mass.)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s10020-023-00680-z,
  title = {Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.},
  author = {Gong J and Yang R and Zhou M and Chang LJ},
  year = {2023},
  journal = {Molecular medicine (Cambridge, Mass.)},
  doi = {10.1186/s10020-023-00680-z},
  url = {https://doi.org/10.1186/s10020-023-00680-z}
}

RIS

TY  - JOUR
TI  - Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.
AU  - Gong J
AU  - Yang R
AU  - Zhou M
AU  - Chang LJ
PY  - 2023
JO  - Molecular medicine (Cambridge, Mass.)
DO  - 10.1186/s10020-023-00680-z
UR  - https://doi.org/10.1186/s10020-023-00680-z
ER  - 

APA

J, G., R, Y., M, Z., & LJ, C. (2023). Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.. Molecular medicine (Cambridge, Mass.). https://doi.org/10.1186/s10020-023-00680-z

Source records